Eric Rowinsky

Executive Chairman at Rgenix, Inc.

Eric Rowinsky

Eric Rowinsky

Executive Chairman at Rgenix, Inc.

Overview
Career Highlights

Rgenix, Inc.
Primrose Therapeutics, Inc.

RelSci Relationships

2579

Number of Boards

26

Birthday

1957

Age

62

Contact Data
Trying to get in touch with Eric Rowinsky? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Eric Rowinsky likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founding Partner at Sarissa Capital Management LP

Relationship likelihood: Strong

Chief Executive Officer at Biogen, Inc.

Relationship likelihood: Strong

Director, Head & Neck Cancer Research Division at Johns Hopkins University

Relationship likelihood: Strong

Chief Executive Officer at Macrophage Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Rgenix, Inc.

Relationship likelihood: Strong

Chairman, President & Chief Executive Officer at Fortress Biotech, Inc.

Relationship likelihood: Strong

Venture Partner at Third Rock Ventures LLC

Relationship likelihood: Strong

Former Co-Director of Drug Development & Gastrointestinal Oncology at Johns Hopkins University

Relationship likelihood: Strong

Director of the Harvard Gene Therapy Initiative at Harvard University - Harvard Medical School

Relationship likelihood: Strong

Chairman at Sofinnova Partners SAS

Relationship likelihood: Strong

Paths to Eric Rowinsky
Potential Connections via
Relationship Science
You
Eric Rowinsky
Executive Chairman at Rgenix, Inc.
Education
B.A. Unknown

Founded in 1831, New York University is now one of the largest private universities in the United States. Of the more than 3,000 colleges and universities in America, New York University is one of only 60 member institutions of the distinguished Association of American Universities. From a student body of 158 during NYU's very first semester, enrollment has grown to more than 40,000 students attending 18 schools and colleges at five major centers in Manhattan and in sites in Africa, Asia, Europe, and South America. Today, students come from every state in the union and from 133 foreign countries. The faculty, which initially consisted of fourteen professors and lecturers (among them artist and inventor Samuel F. B. Morse), now totals over 3,100 full-time members whose research and teaching encompasses the humanities, the sciences, and the social sciences; the law; medicine; business; education; the fine arts, studio art, and the performing and cinematic arts; music; social work; public administration; the ancient world; and continuing and professional studies. With more than 2,500 courses offered, the University awards more than 25 different degrees. Although overall the University is large, the individuals schools and colleges are small- to moderate-sized units—each with its own traditions, programs, and faculty – and there are many communities to be found within the NYU community based on interests, activities, and shared experiences. The center of NYU is its Washington Square campus in the heart of Greenwich Village. One of the city's most creative and energetic communities, the Village is a historic neighborhood that has attracted generations of writers, musicians, artists, and intellectuals. NYU, in keeping with its founder’s vision, is “in and of the city”: the University – which has no walls and no gates – is deeply intertwined with New York City, drawing inspiration from its vitality. In addition to its Manhattan locations, the University is also formally affiliated the Polytechnic Institute of NYU in Brooklyn, the second oldest school of engineering and technology in the country, and has research facilities, notably the Nelson Institute of Environmental Medicine, in Sterling Forest, near Tuxedo, New York. And NYU has established itself as the first global network university, with a comprehensive liberal arts campus in Abu Dhabi – the first to be operated abroad by a major U.S. research university – and other sites for study and research in Accra, Ghana; Berlin, Germany; Buenos Aires, Argentina; Florence, Italy; London, England; Madrid, Spain; Paris, France; Prague, the Czech Republic; Shanghai, China; and Tel Aviv, Israel, among other locations.

MD

Vanderbilt University School of Medicine is a medical school located in Nashville, Tennessee. Currently tied for 14th on the list of accredited medical schools in the U.S News & World Report 2016 rankings, the school of medicine has a reputation as a center of research and high-quality clinical care. Vanderbilt School of Medicine is ranked No. 10 among U.S. medical schools for funding from the National Institutes of Health. Located in the Vanderbilt University Medical Center on the southeastern side of the Vanderbilt University campus, the School of Medicine claims two Nobel laureates: Earl W. Sutherland Jr., in 1971, for his discovery of the metabolic regulating compound cyclic AMP, and Stanley Cohen, in 1986, for his discovery with a colleague of epidermal growth factor.

Career History
Executive Chairman
2015 - Current

Rgenix, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY.

Consultant
2010 - Current

Fortress Biotech, Inc. engages in the development and commercialization of novel pharmaceutical and biotechnology products. It operates through the following segments: Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development, and National. The National segment consists of National Holdings Corporation, an independent brokerage company. The company was founded on June 28, 2006 in and is headquartered in New York, NY.

Independent Consultant
2010 - Current

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Boards & Committees
Member, Scientific Advisory Board
2015 - Current
Member, Scientific Advisory Board
Current

OncoEthix SA operates as a clinical stage biotechnology company which develops cancer drugs. Its products include OTX008, OTX015, and OTX009. The company was founded by Esteban Cvitkovic, Jeanne Kay Noel, Yves Paternot, and Patrice Herait in March 2007 and is headquartered in Luzern, Switzerland.

Member, Clinical Advisory Board
Current

Supratek Pharma, Inc. develops drugs and related oncology therapeutic products. It offers injectable chemotherapeutic that enhances or enables an approved anticancer drug. The firm's products include SP1014C - a novel cabazitaxel against drug resistant prostate cancer, SP1030C - novel bendamustine against chronic lymphocytic leukemia and non-Hodgkin's lymphoma and SP1049C - a novel injectable anthracycline platform drug against chemoresistant cancers. The company was founded by Valery Alakhov in 1994 and is headquartered in Pointe-Claire, Canada.

Member-Scientific Counselors Board
Prior

The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Eric Rowinsky. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Eric Rowinsky's profile does not indicate a business or promotional relationship of any kind between RelSci and Eric Rowinsky.